P2RY12 and cardiovascular disorder: The prevention of cardiovascular disease is obtained via drugs affecting the amplification pathways of platelet aggregation, i.e., aspirin at low doses, which mainly targets the platelet COX-1 and inhibits TXA2, and P2Y12 antagonists, which block the action of ADP [154].